Sandoz to market authorized generic version of Adderall XR

Sandoz, Shire sign five-year license agreement

PHILADELPHIA — Sandoz will market an authorized generic version of an attention deficit hyperactivity disorder drug made by Shire under a contract between the two companies, Shire said Monday.

Shire said Sandoz, the generics division of Swiss drug maker Novartis, would market an authorized generic version of Adderall XR (amphetamine; dextroamphetamine).

Under the five-year agreement, which became effective Sunday, Sandoz will begin marketing the product starting in July 2016. Shire will manufacture the drug, while Sandoz will market it and provide royalties on sales to Shire.

Authorized generics are branded drugs marketed under their generic names at a discounted price, usually under a contract between the branded drug's manufacturer and a third-party company.

 

Login or Register to post a comment.